Compare ONEW & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONEW | STRO |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.2M | 181.4M |
| IPO Year | 2019 | 2018 |
| Metric | ONEW | STRO |
|---|---|---|
| Price | $9.39 | $9.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | $13.33 | ★ $47.23 |
| AVG Volume (30 Days) | 77.3K | ★ 271.7K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,872,334,000.00 | $38,419,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.85 | N/A |
| P/E Ratio | $3.43 | ★ N/A |
| Revenue Growth | ★ 5.62 | N/A |
| 52 Week Low | $8.12 | $0.72 |
| 52 Week High | $17.35 | $43.85 |
| Indicator | ONEW | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 43.17 | 22.90 |
| Support Level | $8.98 | N/A |
| Resistance Level | $9.89 | $16.99 |
| Average True Range (ATR) | 0.53 | 1.23 |
| MACD | 0.07 | -0.15 |
| Stochastic Oscillator | 52.99 | 2.70 |
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.